Protagonist Therapeutics (PTGX) Other Non-Current Liabilities (2015 - 2021)
Protagonist Therapeutics' (PTGX) quarterly Other Non-Current Liabilities came in at $121000.0 in Q3 2021, down 28.82% year-on-year from $170000.0 in Q3 2020, and little changed quarter-over-quarter from $121000.0 in Q2 2021.
Protagonist Therapeutics (PTGX) Other Non-Current Liabilities (2015 - 2021) Analysis & Trends
Protagonist Therapeutics has disclosed Other Non-Current Liabilities across 3 years of filings, most recently posting $121000.0 for Q3 2021.
- Other Non-Current Liabilities for Q3 2021 came in at $121000.0, down 28.82% year-over-year; the trailing twelve-month figure through Sep 2021 was $121000.0 (down 28.82% YoY), and the FY2020 annual result was $121000.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $121000.0 for Q3 2021 at Protagonist Therapeutics, roughly flat from $121000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $170000.0 in Q3 2020 to a low of $92000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Protagonist Therapeutics | 7.35 Bn | 7.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 121,000.00 |
| Jun 30, 2021 | 121,000.00 |
| Mar 31, 2021 | 121,000.00 |
| Dec 31, 2020 | 121,000.00 |
| Sep 30, 2020 | 170,000.00 |
| Jun 30, 2020 | 92,000.00 |
| Dec 31, 2015 | 2.12 Mn |